Connect public, paid and private patent data with Google Patents Public Datasets

Compositions and kits useful for treatment of respiratory illness

Download PDF

Info

Publication number
US20070249727A1
US20070249727A1 US11657860 US65786007A US20070249727A1 US 20070249727 A1 US20070249727 A1 US 20070249727A1 US 11657860 US11657860 US 11657860 US 65786007 A US65786007 A US 65786007A US 20070249727 A1 US20070249727 A1 US 20070249727A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
composition
present
invention
device
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11657860
Inventor
Kelly Lee Martin
Jayant Eknath Khanolkar
Douglas William Gledhill
Susan Elaine Criss
Niranjan Ramji
Elaine Rose Costeines
Thomas Edward Huetter
Radhika R. Iyer
Daren K. Anness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Abstract

The invention relates to a clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof. Also disclosed are kits comprising: a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof.

Description

    FIELD OF THE INVENTION
  • [0001]
    The invention relates to a clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof.
  • BACKGROUND OF THE INVENTION
  • [0002]
    The ability to produce a stable composition can be affected by the type of container or device in which the composition is located. The container can be made of materials that have certain affinities for ingredients contained within the composition for example pharmaceutical actives such phenylephrine, acetaminophen and/or dextromethorphan. The interaction, between the material that the container or device is made of and ingredients comprised within the composition, can result in precipitation of the ingredients and prevent appropriate dissolution of the ingredients within the composition.
  • [0003]
    Because these actives have different properties and stabilities, it is a challenge to formulate overall compositions containing actives wherein the actives are all stable and effective in a device for delivering the compositions and at the same time controlling the levels of ingredients in the composition so as to prevent adverse side effects such as diarrhea.
  • [0004]
    Therefore, the present invention provides suitable ranges of solvent concentrations and ratios that prevent the precipitation of actives, reduce aldehyde levels, and form stable compositions that deliver actives to a consumer in need all within a preferred device.
  • SUMMARY OF THE INVENTION
  • [0005]
    The present invention is directed to a clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
  • [0006]
    The present invention further relates to a kit comprising: a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
  • [0007]
    The invention is further directed to methods of treating respiratory illness and symptoms thereof comprising orally administering a composition as described herein.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0008]
    The present invention comprises a clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
  • [0009]
    These and other limitations of the compositions and methods of the present invention, as well as many of the optional ingredients suitable for use herein, are described in detail hereinafter.
  • [0010]
    All weights, measurements and concentrations herein are measured at 25° C. on the composition in its entirety, unless otherwise specified.
  • [0011]
    All percentages, parts and ratios as used herein are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.
  • [0012]
    The composition and methods of the present invention can comprise, consist of, or consist essentially of, the essential elements and limitations of the invention described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in compositions intended for companion animal consumption.
  • Device
  • [0013]
    The device of present invention preferably contains a composition. Nonlimiting examples of the device of the present invention include a bottle, a canister, a container, and combinations. Preferably, the device is clear. Clear devices can include both colorless and colored which permits the user to see the composition through the device. The device comprises a material. Nonlimiting examples of a material that can be used in the present invention include Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof. Preferably the material of the present invention is PET.
  • Composition
  • [0014]
    The device of the present invention preferably contains a composition. The compositions of the present invention are made stable when placed in devices made of the material described herein. The compositions of the present invention comprise phenylephrine; phenylephrine free forms and addition salt forms, and mixtures thereof. Nonlimiting salts of phenylephrine include phenylephrine hydrochloride and phenylephrine hydrobromide.
  • [0015]
    The compositions of the present invention may comprise an amount of phenylephrine in the range of about 0.0001 mg to about 60 mg of phenylephrine, from about 0.01 to about 30 mg, from about 0.01 to about 20 mg and from about 5 mg to about 10 mg of phenylephrine, all per dose of the composition. By way of non-limiting example, an embodiment of the present invention may comprise about 10 mg of phenylephrine, per dose. Another embodiment of the present invention may comprise about 5 mg of phenylephrine, per dose.
  • [0016]
    The compositions of the present invention may comprise an amount of phenylephrine in the range of from about 0.0001% to about 2%, from about 0.0001% to about 1%, from about 0.001% to about 0.5%, and alternatively from about 0.01% to about 0.25%, all by weight of the composition.
  • [0017]
    The compositions of the present invention may achieve enhanced stability when the composition has a pH of from about 2 to about 6.5, from about 2 to about 5, from about 3.5 to about 5, and from about 4 to about 5. As non-limiting examples, the present compositions may comprise one or more acidulants in order to reach, and maintain, the pH. Acidity can be adjusted to and maintained within the requisite range by known and conventional methods. Acidulant as used herein means a substance added to a composition to lower the pH of the composition.
  • [0018]
    Organic as well as inorganic edible acids may be used to adjust the pH of the compositions herein. The acids can be present in their undissociated form or, alternatively, as their respective salts, for example, potassium or sodium hydrogen phosphate, potassium or sodium dihydrogen phosphate salts. Illustrative acids are edible organic acids which include citric acid, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, or mixtures thereof.
  • [0019]
    The compositions of the present invention are preferably substantially free of aldehydes. As used herein, substantially free of aldehydes means that the composition comprises less than about 0.1%, alternatively less than about 0.05%, alternatively less than about 0.01% of total aldehydes, (i.e. compounds containing at least one aldehydic moiety), all by weight of the composition. As the inventors have discovered, formulating the compositions of the present invention to be substantially free of aldehydes upon manufacture compensates for the potential for formation of some amount of aldehyde in the composition during storage conditions.
  • [0020]
    Aldehydes are compounds that are well known to the ordinarily skilled artisan. Flavors are well known for use in health products for improving consumer acceptance, and many such flavors are aldehydic in structure. For example, characterizing compounds for cherry flavors include benzaldehyde and p-tolyl aldehyde. However, the inventors have found that these same flavors also often cause degradation of the phenylephrine used herein.
  • [0021]
    The present inventors have found that substantial removal of the aldehydes, as defined herein, greatly stabilizes the resulting composition.
  • Additional Pharmaceutical Actives
  • [0022]
    The compositions of the present invention can also comprise at least one additional pharmaceutical active. Pharmaceutical actives are readily known to the ordinarily skilled artisan and, as such, the actives are not bound by the descriptions provided herein. Nonlimiting examples of additional pharmaceutical actives may include, but are not limited to, antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, analgesics, antipyretic anti-inflammatory agents, local anesthetics, anti-inflammatory agents, demulcents, herbal remedies, vitamins, supplements, antioxidants, natural ingredients, minerals, energy boosting ingredients, sleep aids and immune system boosting ingredients, and mixtures thereof.
  • [0023]
    Nonlimiting examples of additional pharmaceutical actives include but are not limited to dextromethorphan, acetaminophen, ephedrine, pseudoephedrine, phenylpropanolamine, ibuprofen, aspirin, ketoprofen, guaifenesin, ambroxyl, bromhexine, diphenhydramine, chlorpheniramine, doxylamine, triprolidine, clemastine, pyrilamine, promethazine, cetirizine, loratidine, oxycodone, hydrocodone, naproxen, brompheniramine, carbinoxamine, caffeine, benzonatate, pheniramine, fentanyl, azatedine, desloratadine, carbamazepine, buprenorphine, hydromorphone, indomethacin, oxymorphone, phenol, codeine, mesalamine, dichlophenac, sulindac, beclomethaxone, meloxicam, fenoproten, mometasone, menthol, benzocaine, dipyridamole, methscopolamine, the free and the addition salt forms, chamomile, passion flower, Vitamin C, Vitamin D, B Vitamins, echinacea, melatonin, green tea, curcumin, zinc, selenium, calcium, guarana, probiotics and mixtures thereof.
  • [0024]
    Preferably the additional pharmaceutical actives include but are not limited to dextromethorphan, acetaminophen, doxylamine, and guaifenesin.
  • [0025]
    The compositions of the present invention may comprise an amount of at least one additional pharmaceutical active in the range of about zero (0) mg to about 1,000 mg of each of at least one additional pharmaceutical active, alternatively from about 2.5 mg to about 750 mg, and alternatively from about 5 mg to about 650 mg of each of at least one additional pharmaceutical active, all per dose of the composition.
  • [0026]
    The compositions of the present invention may comprise an amount of additional pharmaceutical active in the range of about 0% to about 15%, alternatively 0.0001% to about 10%, alternatively from about 0.001% to about 7%, and alternatively from about 0.01% to about 5%, all by weight of the composition.
  • Sweeteners
  • [0027]
    The composition of the present invention may comprise a sweetener to provide sweetness and aid in the taste masking of a pharmaceutical active(s) as well as to provide some body and thickness. When a sweetener is present in the present inventive composition, the compositions may comprise from about 0.0001% to about 30% sweetener, from about 0.0001% to about 20% sweetener, alternatively from about from about 0.0001% to about 10% sweetener, alternatively from about from about 0.0001% to about 2% sweetener and alternatively from about 0.05% to about 1.0% sweetener, all by weight of the composition. The sweeteners of the present invention can be artificial sweeteners and/or natural sweeteners.
  • [0028]
    Non-limiting examples of artificial sweeteners are selected from the group consisting of sodium saccharine, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, and mixtures thereof. Generally, such artificial sweeteners are solids when used in sweetening compositions such as those of the present invention.
  • [0029]
    When an artificial sweetener is present in the present inventive composition, the compositions may comprise from about 0.0001% to about 5% artificial sweetener, from about 0.0001% to about 3.5% artificial sweetener, alternatively from about from about 0.0001% to about 2.0% artificial sweetener, alternatively from about from about 0.0001% to about 1.0% artificial sweetener and alternatively from about 0.05% to about 1.0% artificial sweetener, all by weight of the composition.
  • [0030]
    Nonlimiting examples of natural sweeteners include sucrose, fructose, glucose, glycerin, sorbitol, maltitol, and mannitol and combinations thereof. Sucrose, or table sugar, often in liquid form, may be used. However, sucrose can hydrolyze to its constituent sugars, namely glucose and fructose. Glucose is an aldehyde, and therefore may be less desirable for use herein. However, the present inventors discover herein that the effect of a sweetener on phenylephrine is less than that of traditional aldehyde-containing flavors and aromas. Nonetheless, improved stability can be achieved when low levels of sweeteners are used, in addition to inclusion of a non-aldehydic aesthetic agent if an aesthetic agent is used, such that the composition remains substantially free of aldehydes as described herein. Relatively highly pure grades of sweeteners, having undergone less hydrolysis to monosaccharides, may assist in lowering levels of aldehydes as well. High fructose corn syrup can also be used, though is less desirable because it contains aldehydes.
  • [0031]
    The compositions of the present invention can contain natural sweeteners, such as sucrose. If the natural sweeteners are present in a liquid solution, then the natural sweeteners are present in the range of from about 5% to about 30% by weight of the natural sweeteners solution, and alternatively from about 10% to about 25% by weight of the natural sweeteners solution, wherein the natural sweeteners solution can comprise from about 15% to about 20% by weight of the natural sweeteners solution. If the natural sweeteners are present but not in a liquid solution, then the natural sweeteners are present in the range of from about 4% to about 20% by weight composition, and alternatively from about 8% to about 17% by weight of the composition, wherein the natural sweeteners solution can comprise from about 10% to about 13% by weight of the composition.
  • Additional Ingredients
  • [0032]
    Any or all components typically associated with respiratory illness and symptom treatment products can be used as required or as additional ingredients herein. Nonlimiting examples of additional ingredients include solvents, reducing agents, chloride salt, non-aldehydic aesthetic agent, coolant, colorant, preservative, fragrance, and combinations thereof.
  • Solvents
  • [0033]
    The composition of the present invention can comprise a solvent. In one embodiment, the solvent is water-soluble or water miscible. As used herein, solvent means a substance used to dissolve phenylephrine and/or other pharmaceutical active(s). Non-limiting examples of solvents may be selected from water, propylene glycol, ethanol, glycerol, sorbitol, and mixtures thereof.
  • [0034]
    In one embodiment, the solvent is selected from water, propylene glycol, ethanol, polyethylene glycol (PEG) and mixtures thereof. There are also mixtures of the solvents that may be useful for certain product forms of the present invention. For example, wherein the product form is an elixir, liquid-filled capsule or liquid-filled lozenge, the solvent may optionally be a mixture of propylene glycol, ethanol, and water. Additionally, for example, when the product form is a liquid filled capsule, or liquid filled lozenge the solvent may optionally be PEG and water.
  • [0035]
    The level of each solvent that makes up the mixture is dependent on the solubility of the active(s) and the aesthetic benefits sought by the formulator. For example, for the compositions of the present invention, the composition may optionally comprise from about 40% to about 95% total solvents, or from about 50% to about 90%, or from about 60% to about 85% total solvents, all by weight of the composition.
  • Chelating Agent
  • [0036]
    The present compositions may optionally comprise a chelating agent. It has been found that trace amounts of heavy metal ions may catalyze auto-oxidation reactions that may compromise stability of the final composition.
  • [0037]
    The compositions may therefore optionally include a chelating agent. Chelating agents are well known to the ordinarily skilled artisan. Non-limiting examples of chelating agents include but are not limited to the salts of disodium and calcium salts of ethylene diamine tetraacetic acid (EDTA), tetrasodium EDTA, sodium hexametaphosphate (SHMP), citric acid, phosporic acid, di(hydroxyethyl)glycine, 8-hydroxyquinoline, and mixtures thereof. Trivalent metal chelating agents such as galactomannans complexed with iron may also be useful.
  • [0038]
    Wherein the compositions herein comprise a chelaing agent, the compositions may optionally comprise from about 0.0001% to about 1% of the chelating agent, alternatively from about 0.001% to about 0.5%, and alternatively from about 0.01% to about 0.3% of the chelating agent, all by weight of the composition.
  • Reducing Agents
  • [0039]
    The present compositions may also optionally comprise a reducing agent. The inclusion of a reducing agent may have a beneficial chemical stabilizing effect on the pharmaceutical actives used in the present invention. Therefore, the reducing agents useful in the composition depend on the active selected and its solubility.
  • [0040]
    As used herein, the reducing agent is a substance that has a lower redox potential than the pharmaceutical active or other adjuvant that it is intended to protect from oxidation. Thus, reducing agents are more readily oxidized than the pharmaceutical active or other adjuvant and are effective in the presence of oxidizing agents.
  • [0041]
    Reducing agents have an “electrode potential value”. The electrode potential value is defined by the Nernst equation and measured using standard electrochemical reference cells. The resulting values are therefore called the “Standard Electrode Potential”, or E0, as measured in volts (V). Comparing Standard Electrode Potentials for different substances can be used to assess the effectiveness of different reducing agents.
  • [0042]
    The reducing agents useful in the present invention may optionally have E0 values greater than about −0.119V, and alternatively from about −0.119V to +0.250V. Illustrative reducing agents are selected from the salts of metabisulfite and bisulfite, including their sodium and potassium salts, dithiothreitol, thiourea, sodium thiosulphate, thioglycolic acid, tert-butyl hydroquinone (TBHQ), acetyl cysteine, hydroquinone, salts thereof, and mixtures thereof.
  • [0043]
    Wherein a reducing agent is utilized, the present compositions may comprise from about 0.001% to 1%, alternatively from about 0.01% to about 0.5%, and alternatively from about 0.05% to about 0.1% of a reducing agent, all by weight of the composition.
  • Salts
  • [0044]
    The present compositions may optionally comprise a salt, such as a chloride salt, which has been further discovered to provide potential stability benefits. Non-limiting examples include sodium chloride, potassium chloride, ammonium chloride, and mixtures thereof.
  • [0045]
    Wherein the composition comprises a salt, the composition may optionally comprise from about 0.0001% to about 2%, alternatively from about 0.25% to about 1% of the salt, all by weight of the composition. Such salts may slow the dissociation of a pharmaceutical active from the hydrochloride salt of a pharmaceutical active. For example, having a chloride salt present slows the dissociation of phenylephrine from phenylephrine hydrochloride.
  • Non-Aldehydic Aesthetic Agent
  • [0046]
    The present compositions may also optionally comprise a non-aldehydic aesthetic agent. Given the desire to provide compositions that are aesthetically acceptable, the present invention further provides optional alternatives to typical flavors and aromas containing significant levels of aldehyde. Such alternatives are herein referenced as non-aldehydic aesthetic agents.
  • [0047]
    The inventors have discovered that typical flavors and aromas may be substituted with non-aldehydic aesthetic agents such as flavor components which are selected from the group consisting of esters, ketones and alcohols, and also sweeteners, and mixtures thereof, in order to formulate flavors that smell and taste like cherry or other desired flavors.
  • [0048]
    As further examples, the present compositions may comprise a non-aldehydic aesthetic agent such as an ester selected from the group consisting of ethyl butyrate, benzyl acetate, benzyl butyrate, allyl isovalerate, allyl caproate, ethyl-2-methyl butyrate, ethyl methyl phenyl glycidate, and mixtures thereof. The compositions of the present invention may optionally contain from about 0.0001% to about 5%, alternatively from about 0.01% to about 2%, and alternatively from about 0.025% to about 1.5% of non-aldehydic aesthetic agents, all by weight of the composition. Utilizing these fruity esters can readily generate flavors similar to cherry and berry flavors. The body of the flavor may also be important to make it take on character and endure. The use of ketones such as ionones are useful for this purpose. To illustrate, oxanone (4-(p-hydroxyphenyl)-2-butanone, raspberry ketone) along with trace amounts of ionones can provide this body.
  • [0049]
    As a further example, compounds such as cis-3-hexenol and trans-2-hexenyl acetate may add to the flavor. Furaneol and maltol may add a candy-like nuance. In addition, the compositions of the present invention may optionally comprise low-aldehyde juice concentrates as flavoring agents.
  • [0050]
    Methods of the Present Invention
  • [0051]
    In a further embodiment, the present invention is directed to methods of treating a respiratory illness comprising orally administering a composition as described herein to a mammal in need of such treatment. As used herein, the term “respiratory illness” encompasses a broad range of respiratory ailments, including viral infections such as influenza and common cold, as well as allergy, sinusitis, rhinitis, and the like. As further used herein, “treatment” with respect to respiratory illness means that administration of the referenced composition prevents, alleviates, ameliorates, inhibits, or mitigates one or more symptoms of the respiratory illness or the respiratory illness itself, or any like benefit with respect to the respiratory illness in a mammalian subject in need thereof, preferably in humans.
  • [0052]
    The present invention can also be directed to methods of prevention including preventing a respiratory illness or its associated symptoms from occurring in a mammal, for example when the mammal is predisposed to acquiring the respiratory illness, but has not yet been diagnosed with the illness; inhibiting the respiratory illness or its associated symptoms; and/or alleviating, reversing, or curing the respiratory illness or its associated symptoms. Insofar as the methods of the present invention are directed to preventing a respiratory illness, it is understood that the term “prevent” does not require that the respiratory illness be completely thwarted. Rather, as used herein, the term “preventing” or the like refers to the ability of the skilled artisan to identify susceptibility to respiratory illness (such as, for example, in humans during winter months), such that administration of the referenced compositions may occur prior to the onset of the symptoms associated with the illness.
  • [0053]
    The present invention can also be directed to methods of recovery including compositions that boost the energy of the mammal and boost the immune system.
  • [0054]
    Respiratory illness may present as any of a variety of symptoms, such as runny nose, nasal or chest congestion, cough, sneezing, pressure, headache, aches, fever, or sore throat. The mammal treated may be a human.
  • [0055]
    As used herein, the term “orally administering” with respect to the mammal means that the mammal ingests or is directed to ingest, or does ingest, one or more of the present compositions. Wherein the human is directed to ingest the composition, such direction may be that which instructs and/or informs the human that use of the composition may and/or will provide the relief from the respiratory illness (e.g. symptomatic relief, whether temporary or permanent) for example, relief from congestion. For example, such direction may be oral direction (e.g., through oral instruction from, or example, a physician, pharmacists, or other heath professional), radio or television media (i.e., advertisement), or written direction (e.g., through written direction from, for example a physician, pharmacist, or other health professional (e.g., scripts), sales professional or organization (e.g., through, for example, marketing brochures, pamphlets, or other instructive paraphernalia), written media (e.g., internet, electronic mail, or other computer-related media), and/or packaging associated with the composition (e.g., a label present on a container holding the composition). As used herein, “written” means through words, pictures, symbols, and/or other visible or tactile descriptors, such as Braille. Such information need not utilize the actual words used herein, for example, “respiratory”, “illness”, or “mammal”, but rather use of words, pictures, symbols and the like conveying the same or similar meaning are contemplated within the scope of this invention.
  • [0056]
    Administration may be on an as-needed or as-desired basis, for example, once-monthly, once-weekly, or daily, including multiple times daily, for example, at least once daily, twice daily, three times daily, or four times daily or more.
  • [0057]
    The amount of composition administered may be dependent on a variety of factors, including the general quality of health of the mammal, type of mammal, age, gender, or severity of symptoms.
  • [0058]
    In one embodiment herein, the device delivers composition that is administered to the mammal in total dosage volumes, per dose, of from about 5 mL to about 50 mL of the composition, alternatively of from about 10 mL to about 30 mL of the composition.
  • Kit
  • [0059]
    The present invention can also comprise a kit. The kit of the present invention can comprise: a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
  • [0060]
    The kit may further comprise at least one additional pharmaceutical active. The kit may also comprise an additional composition of the present invention in a full size, a sample size or both. The kit may further comprise an additional composition that coordinates with the composition that is comprised within the device or attached to the outside of the device. For, example if the composition contained in the device is a composition for the relief from congestion, the coordinating composition may be for a headache. As well, if the composition in the device is a composition for runny nose, nasal or chest congestion, cough, sneezing, pressure, headache, aches, fever, or sore throat, the coordinating composition may be a vitamin. The kit may further comprise a coupon, rebate, or advertisement. The kit may further comprise a set of instructions. These instructions may also include illustrations.
  • EXAMPLES
  • [0061]
    The following examples further describe and demonstrate embodiments within the scope of the present invention. They are given for the purpose of illustration and are not to be construed as limitations of the present invention.
  • Examples
  • [0062]
    Below are illustrated various non-limiting examples of compositions of the present invention.
  • [0000]
    % w/w % w/w
    Raw Materials Ex. 1 Ex. 2
    Propylene Glycol 40 30
    Doxylamine Succinate 0.08 0.08
    Dextromethorphan HBr 0.13 0.13
    Acetaminophen 4.43 4.43
    Alcohol 8.52 8.52
    Anethole 0.01 0.01
    (Flavoring Agent)
    Glycerin 10 10
    Green Shade 0.005 0.005
    Sodium Citrate 0.17 0.17
    anhydrous
    Citric Acid 0.36 0.36
    (Anhydrous)
    Phenylephrine HCl 0.07 0.07
    Sodium Saccharin 0.07 0.07
    Sucrose Sweetner 31.11 21.16
    solution
    Disodium EDTA 0.05
    Sorbitol Liquid 70% 20
    Beta Carotene
    Water to 100% QS QS
    pH 4.16 4.10
    Green Shade available from Sensient Pharmaceuticals Tech, St. Louis, MO, USA

    Examples 1 and 2 can be made by first, add propylene glycol, alcohol and glycerin to a clean vessel. The additional pharmaceutical active(s), including, for example, acetaminophen, dextromethorphan, and doxylamine, then flavor is added and stirred until dissolved. In a separate vessel, water is added to dissolve phenylephrine, color, buffering agents, sweeteners, and EDTA. The aqueous solution is added to the propylene glycol solution. The resulting composition is mixed with sweetener solution and additional water and the composition is mixed until homogeneous and then placed in a device comprising the material PET.
  • [0000]
    % w/w % w/w
    RAW MATERIAL Ex. 3 Ex. 4
    Water QS QS
    Sodium Carboxymethylcellulose 0.10 0.089
    Sucrose sweetener solution 17 17.825
    Phenylephrine HCl 0.07 0.06
    Propylene Glycol 40 35.6
    Sorbitol 20 17.8
    Glycerin 5 4.45
    Dextromethorphan HBr 0.13 0.11
    Alcohol 4.25 3.79
    Coolant 0.02 .01
    Flavor 0.33 0.30
    Sodium Benzoate 0.1 0.089
    Citric Acid 0.14 0.12
    Sodium Chloride 0.50 0.44
    Sodium Saccharin 0.09 0.08
    Coloring Agent 0.003 0.026
    pH 4.5 4.7
    Coolant available from Takasago International Corp., Tokyo, Japan flavor available from IFF, Dayton, NJ, USA
    Coloring Agent available from Sensient Pharmaceuticals Tech, St. Louis, MO, USA

    Examples 3 and 4 can be made by first, add propylene glycol, and alcohol to a clean vessel. The additional pharmaceutical active(s), including, for example, acetaminophen and dextromethorphan, then flavor is added and stirred until dissolved. In a separate vessel, water is added to dissolve phenylephrine, color, buffering agents, and sweeteners. The aqueous solution is added to the propylene glycol solution. The resulting composition is mixed with sucrose sweetener solution and additional water and the composition is mixed until homogeneous and then placed in a device comprising the material PET.
  • [0000]
    Ex. 5 Ex. 6
    Raw Material wt/wt wt/wt
    PROPYLENE GLYCOL USP 23.0202 22.7066
    SORBITOL SOLUTION 13.1544 12.9752
    GLYCERIN 8 8
    Sucrose Sweetener solution 0 5
    DEXTROMETHORPHAN 0.0614 0.0606
    HYDROBROMIDE, USP
    Acetaminophen, USP 1.9951 1.9679
    PHENYLEPHRINE HYDROCHLORIDE 0.0319 0.0315
    Di sodium EDTA 0.05 0.05
    Coolants 0.03 0.03
    SODIUM BENZOATE NF, FCC 0.1 0.1
    CITRIC ACID USP ANHYDROUS 0.2208 0.2245
    Sodium Citrate, Dihydrate, USP 0.2035 0.2065
    SODIUM CHLORIDE USP 0.5 0.5
    SACCHARIN SODIUM USP 0.1 0.1
    Sucralose 0.07 0.07
    FD&C Yellow #6 0.067 0.067
    SODIUM CMC TYPE 7HOF USP 0.33 0.33
    Flavorant 0.234 0.234
    Water QS QS
    pH 4.5 4.5

    Examples 5 and 6 can be made by first, add propylene glycol, and water to a clean vessel. The additional pharmaceutical active(s), including, for example, acetaminophen and/or dextromethorphan, then flavor is added and stirred until dissolved. In a separate vessel, water is added to hydrate sodium CMC and dissolve phenylephrine, color, buffering agents, sweeteners, preservatives, sodium chloride and EDTA. The aqueous solution is added to the propylene glycol solution. The resulting composition is mixed with sucrose sweetener solution, sorbitol, glycerin and additional water and the composition is mixed until homogeneous and then placed in a device comprising the material PET.
  • [0063]
    All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.
  • [0064]
    While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims (21)

1. A clear device: comprising a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
2. The clear device of claim 1, wherein said material is Polyethylene Terephthalate (PET).
3. The clear device of claim 1, wherein said composition has a pH of from about 2 to about 6.5.
4. The clear device of claim 1, wherein said composition has a pH of from about 2 to about 5.
5. The clear device of claim 1, comprising from about 0.0001% to about 2% pharmaceutical active, by weight of the composition.
6. The clear device of claim 1, wherein said composition further comprising a sweetener.
7. The clear device of claim 6, wherein said sweetener comprises an artificial sweetener.
8. The clear device of claim 7, wherein said artificial sweetener is selected from the group consisting of: sodium saccharin, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, and mixtures thereof.
9. The clear device of claim 8, comprising from about 0.0001% to about 1% of said artificial sweetener, by weight of said composition.
10. The clear device of claim 1, wherein said composition further comprising at least one additional pharmaceutical active.
11. The clear device of claim 10, wherein said additional pharmaceutical active is selected from the group consisting of antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, analgesics, antipyretic anti-inflammatory agents, local anesthetics, anti-inflammatory agents, demulcents, herbal remedies, vitamins, supplements, antioxidants, natural ingredients, minerals, energy boosting ingredients, sleep aids and immune system boosting ingredients, and mixtures thereof.
12. The clear device of claim 1, wherein said composition further comprising a chelating agent.
13. The clear device of claim 12, wherein said chelating agent is selected from the group consisting of: ethylene diamine tetraacetic acid (EDTA), tetrasodium EDTA, sodium hexametaphosphate (SHMP), citric acid, phosphoric acid, di(hydroxyethyl)glycine, 8-hydroxyquinoline, salts thereof and mixtures thereof.
14. The clear device of claim 12, comprising from about 0.0001% to about 2% of said chelating agent, by weight of said composition.
15. The clear device of claim 1, wherein said composition further comprising an additional ingredient selected from the group consisting of a solvent, a reducing agent. a non-aldehydic aesthetic agent, a chloride salt, a coolant, a colorant, a preservative, a fragrance, and combinations thereof.
16. The clear device of claim 1, wherein said device delivers from about 5 ml to about 50 ml of said composition per dose.
17. The clear device of claim 16, wherein said composition is administered at least once daily.
18. A kit comprising: a composition contained in a device; wherein said composition comprising a pharmaceutical active selected from the group consisting of phenylephrine, its free and addition salt forms, and mixtures thereof; and wherein said device comprises a material selected from the group consisting of Polyethylene Terephthalate (PET), Glycol-modified Polyethylene Terephthalate (PETG), Oriented Polypropylene (OPP), Polyvinylchloride (PVC), Polyvinylidene Chloride (PVDC), Nylon, Polyethylene Terphthalate Polyester (PETP), Polyphene, and combinations thereof.
19. The kit of claim 18, further comprising a set of instructions.
20. The kit of claim 18, wherein said composition further comprising at least one additional pharmaceutical active.
21. The kit of claim 18, wherein said kit further comprising at least one additional pharmaceutical active.
US11657860 2006-04-21 2007-01-25 Compositions and kits useful for treatment of respiratory illness Abandoned US20070249727A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11408299 US20070249566A1 (en) 2006-04-21 2006-04-21 Compositions and methods useful for treatment of respiratory illness
US11657860 US20070249727A1 (en) 2006-04-21 2007-01-25 Compositions and kits useful for treatment of respiratory illness

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11657860 US20070249727A1 (en) 2006-04-21 2007-01-25 Compositions and kits useful for treatment of respiratory illness
EP20070735602 EP2046289B1 (en) 2006-04-21 2007-04-20 Compositions and kits of phenylephrine
PCT/IB2007/051470 WO2007122581A3 (en) 2006-04-21 2007-04-20 Compositions and kits of phenylephrine
CA 2650036 CA2650036C (en) 2006-04-21 2007-04-20 Compositions and kits useful for treatment of respiratory illness
JP2009506029A JP5362549B2 (en) 2006-04-21 2007-04-20 Useful compositions and kits for the treatment of respiratory diseases
CN 200780014329 CN101631539A (en) 2006-04-21 2007-04-20 Compositions and kits useful for treatment of respiratory illness
ES07735602T ES2454967T3 (en) 2006-04-21 2007-04-20 Compositions and kits of phenylephrine
US15384369 US20170100391A1 (en) 2006-04-21 2016-12-20 Compositions And Kits Useful For Treatment Of Respiratory Illness

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11408299 Continuation-In-Part US20070249566A1 (en) 2006-04-21 2006-04-21 Compositions and methods useful for treatment of respiratory illness

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15384369 Continuation US20170100391A1 (en) 2006-04-21 2016-12-20 Compositions And Kits Useful For Treatment Of Respiratory Illness

Publications (1)

Publication Number Publication Date
US20070249727A1 true true US20070249727A1 (en) 2007-10-25

Family

ID=48805455

Family Applications (2)

Application Number Title Priority Date Filing Date
US11657860 Abandoned US20070249727A1 (en) 2006-04-21 2007-01-25 Compositions and kits useful for treatment of respiratory illness
US15384369 Pending US20170100391A1 (en) 2006-04-21 2016-12-20 Compositions And Kits Useful For Treatment Of Respiratory Illness

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15384369 Pending US20170100391A1 (en) 2006-04-21 2016-12-20 Compositions And Kits Useful For Treatment Of Respiratory Illness

Country Status (7)

Country Link
US (2) US20070249727A1 (en)
JP (1) JP5362549B2 (en)
CN (1) CN101631539A (en)
CA (1) CA2650036C (en)
EP (1) EP2046289B1 (en)
ES (1) ES2454967T3 (en)
WO (1) WO2007122581A3 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20110083985A1 (en) * 2009-10-12 2011-04-14 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
WO2014127118A1 (en) * 2013-02-13 2014-08-21 The Procter & Gamble Company Anise flavored medication
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
WO2016024928A1 (en) * 2014-08-14 2016-02-18 Biofarma İlaç Sanayi Ve Ticaret A.Ş. Taste masked paracetamol formulations

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US6187340B1 (en) * 1997-09-10 2001-02-13 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical preparation
US20020061340A1 (en) * 2000-09-20 2002-05-23 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US20030118654A1 (en) * 2001-12-07 2003-06-26 B. Santos Joyce Bedelia Taste masked aqueous liquid pharmaceutical composition
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
US20040162273A1 (en) * 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
US20040259952A1 (en) * 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US20060121066A1 (en) * 2001-07-31 2006-06-08 David Jaeger Sucralose formulations to mask unpleasant tastes
US20060148837A1 (en) * 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US20070197661A1 (en) * 2006-02-21 2007-08-23 Wyeth Phenylephrine liquid formulations
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780760B2 (en) * 1986-07-28 1995-08-30 ライオン株式会社 Fuenirefurin-based solutions that are stabilized
JP3256997B2 (en) * 1990-08-30 2002-02-18 千寿製薬株式会社 Stable aqueous formulations
JP3021312B2 (en) * 1994-03-15 2000-03-15 千寿製薬株式会社 Plano of flurbiprofen stabilization method and stable pranoprofen aqueous solutions
JP3262091B2 (en) * 1998-12-25 2002-03-04 ライオン株式会社 Collyrium composition, a method to eliminate the stickiness of collyrium composition and set eyewash
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP2003063962A (en) * 2001-08-29 2003-03-05 Taisho Pharmaceut Co Ltd Composition for rhinostenosis
US20040132827A1 (en) * 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
JPWO2004037293A1 (en) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 Stabilizing composition
JP2005247802A (en) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd Eye drops

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US6187340B1 (en) * 1997-09-10 2001-02-13 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical preparation
US20020061340A1 (en) * 2000-09-20 2002-05-23 Lee Shahinian Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US20060121066A1 (en) * 2001-07-31 2006-06-08 David Jaeger Sucralose formulations to mask unpleasant tastes
US20040259952A1 (en) * 2001-11-29 2004-12-23 Richat Abbas Formulations for oral administration of cromolyn sodium
US20030118654A1 (en) * 2001-12-07 2003-06-26 B. Santos Joyce Bedelia Taste masked aqueous liquid pharmaceutical composition
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
US20040162273A1 (en) * 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
US20060148837A1 (en) * 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
US20070197661A1 (en) * 2006-02-21 2007-08-23 Wyeth Phenylephrine liquid formulations
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Pharmaceutical and Medical Packaging (PMP, July 1998) *
Remington (Science and Practice of Pharmacy, Nineteenth edition, vol. 1, p 806, 1995, p 1-4) *
The United States Pharmacopeia (USP 23, NF 18, 1995) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20110083985A1 (en) * 2009-10-12 2011-04-14 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
CN102647971A (en) * 2009-10-12 2012-08-22 贝林格尔.英格海姆维特梅迪卡有限公司 Containers for compositions comprising meloxicam
US9101529B2 (en) * 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9186296B2 (en) 2009-10-12 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
WO2014127118A1 (en) * 2013-02-13 2014-08-21 The Procter & Gamble Company Anise flavored medication
US9457085B2 (en) 2013-02-13 2016-10-04 The Procter & Gamble Company Anise flavored medication
RU2625550C2 (en) * 2013-02-13 2017-07-14 Дзе Проктер Энд Гэмбл Компани Anis-aromatised drug
US9839620B2 (en) 2013-02-13 2017-12-12 The Procter & Gamble Company Anise flavored medication
WO2016024928A1 (en) * 2014-08-14 2016-02-18 Biofarma İlaç Sanayi Ve Ticaret A.Ş. Taste masked paracetamol formulations

Also Published As

Publication number Publication date Type
CA2650036C (en) 2012-10-23 grant
JP5362549B2 (en) 2013-12-11 grant
JP2009535305A (en) 2009-10-01 application
US20170100391A1 (en) 2017-04-13 application
CA2650036A1 (en) 2007-11-01 application
WO2007122581A2 (en) 2007-11-01 application
EP2046289A2 (en) 2009-04-15 application
EP2046289B1 (en) 2014-01-29 grant
WO2007122581A3 (en) 2009-07-02 application
CN101631539A (en) 2010-01-20 application
ES2454967T3 (en) 2014-04-14 grant

Similar Documents

Publication Publication Date Title
US5204118A (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US20080021104A1 (en) Liquid compositions of calcium acetate
US20020147201A1 (en) Water soluble and palatable complexes
US7452872B2 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US6391886B1 (en) Oral compositions having improved consumer aesthetics
US6589555B2 (en) Effervescent vitaceutical compositions and related methods
US20070160689A1 (en) Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
WO2001022967A1 (en) Compositions having improved stability
WO2000041693A2 (en) Compositions having improved delivery of actives
US20090176884A1 (en) Pharmaceutical suspension composition
US20080026055A1 (en) Chewable tablet containing phenylephrine
US20020086878A1 (en) Compositions having improved stability
EP0426479B1 (en) Use of a composition for the manufacture of a medicament for curing the symptoms of overindulgence
KR20100138768A (en) Fast dissolving oral dosage form containing steviosides as a taste masking agent
JP2002363105A (en) Method for masking unpleasant taste and solution for oral administration
US20080014274A1 (en) Enhanced stability phenylephrine liquid compositions
US20070197661A1 (en) Phenylephrine liquid formulations
JP2002255852A (en) Spray preparation for stomatitis
Nagaraju et al. Comprehensive review on oral disintegrating films
JP2008308417A (en) Medicinal composition of antimycotic agent
US20080171089A1 (en) Stable anti-nausea oral spray formulations and methods
US5534552A (en) Clear non-alcoholic sinus and allergy medication
US20090155189A1 (en) Preparations, Methods and Kits Useful for the Treatment of Cough
JP2004161679A (en) Liquid preparation for internal use
Smith et al. Bath salts as a “legal high”

Legal Events

Date Code Title Description
AS Assignment

Owner name: PROCTER & GAMBLE COMPANY, THE, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARTIN, KELLY LEE;KHANOLKAR, JAYANT EKNATH;GLEDHILL, DOUGLAS WILLIAM;AND OTHERS;REEL/FRAME:019206/0682;SIGNING DATES FROM 20070328 TO 20070423